Yeah I've been doing some DD tonight myself. Looks like IV uti trial data is next catalyst due soon, literally anyday. Then theres a lot to expect for 2018. With positive uti data they will start with the oral trial again in phase 2 accounting for the food effect. Positive uti also means additional sNDA filing with FDA for that indication. They said the expectation is FDA will have already approved for ciai by then so that approval will also be a catalyst. EU will prob approve by then too.
Adding the UTI indication should allow a much larger market cap. I've seen some discussion where the idea is this should allow for the share price to appreciate significantly. Market is basically using a prove it approach here. Guess we will see. Lots of potential. Many analysts with price targets way way higher than we are now. I sure do hope this is the year they get eravacycline approved and make back a lot of that lost market cap value.
News 
Market Data 
Discover 
